Related resources
Full-text held externally
- DOI: 10.1038/nrd3869
- PMID: 23123941
- UKPMCID: 23123941
Search for item elsewhere
University researcher(s)
Academic department(s)
Drug repositioning for Alzheimer's disease.
Corbett, Anne; Pickett, James; Burns, Alistair; Corcoran, Jonathan; Dunnett, Stephen B; Edison, Paul; Hagan, Jim J; Holmes, Clive; Jones, Emma; Katona, Cornelius; Kearns, Ian; Kehoe, Patrick; Mudher, Amrit; Passmore, Anthony; Shepherd, Nicola; Walsh, Frank; Ballard, Clive
Nature reviews. Drug discovery. 2012;11(11):833-846.
Access to files
Full-text and supplementary files are not available from Manchester eScholar. Full-text is available externally using the following links:
Full-text held externally
- DOI: 10.1038/nrd3869
- PMID: 23123941
- UKPMCID: 23123941
Abstract
Existing drugs for Alzheimer's disease provide symptomatic benefit for up to 12 months, but there are no approved disease-modifying therapies. Given the recent failures of various novel disease-modifying therapies in clinical trials, a complementary strategy based on repositioning drugs that are approved for other indications could be attractive. Indeed, a substantial body of preclinical work indicates that several classes of such drugs have potentially beneficial effects on Alzheimer's-like brain pathology, and for some drugs the evidence is also supported by epidemiological data or preliminary clinical trials. Here, we present a formal consensus evaluation of these opportunities, based on a systematic review of published literature. We highlight several compounds for which sufficient evidence is available to encourage further investigation to clarify an optimal dose and consider progression to clinical trials in patients with Alzheimer's disease.